Inovio receives FDA accelerated approval for VOCERYQ, its first commercial product
+1 new source since this summary was written
The U.S. Food and Drug Administration granted accelerated approval to Inovio Pharmaceuticals' VOCERYQ for treating recurrent respiratory papillomatosis, marking the company's first marketed therapy. The approval triggered a pre‑open rally of roughly 225% with the share price climbing to about $1.96. In addition, a court awarded Inovio a $80.4 million judgment against former suppliers, and the firm plans to begin shipping the product within about 60 days, with full commercial rollout targeted for the first quarter of 2027.
Why it matters
The approval creates a new revenue stream for Inovio, with the company estimating a $460,000 price for the full regimen and a U.S. patient pool of about 25,000 adults, which could generate significant sales (the company says). The court judgment also improves the balance sheet by adding $80.4 million in recoverable damages.
Key facts
- 1Inovio's shares jumped roughly 225% in pre‑open trading, reaching $1.96 per share. investing.com
- 2The FDA granted accelerated approval to VOCERYQ for recurrent respiratory papillomatosis. investing.com
- 3A U.S. court awarded Inovio a judgment of $80.4 million against VGXI and GeneOne Life Science. investing.com
- 4Inovio expects to begin shipping VOCERYQ in about 60 days and to achieve full commercial deployment in Q1 2027. investorideas.com
- 5In the pivotal RRP‑001 study, 27% of patients required no surgery after 12 months of treatment. investorideas.com
- 6The company projects a price of $460,000 for the complete VOCERYQ regimen. finance.yahoo.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.